SymBio Pharmaceuticals Limited (TYO:4582)
Japan · Delayed Price · Currency is JPY 78.00
-1.00 (-1.27%)
May 29, 2026, 3:30 PM JST
SymBio Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,277 | 1,307 | 2,452 | 5,589 | 10,008 | 8,257 |
| 1,277 | 1,307 | 2,452 | 5,589 | 10,008 | 8,257 | |
Revenue Growth (YoY) | -39.73% | -46.70% | -56.13% | -44.16% | 21.21% | 176.42% |
Cost of Revenue | 359.33 | 360 | 579 | 1,179 | 2,408 | 2,452 |
Gross Profit | 917.76 | 947 | 1,873 | 4,410 | 7,600 | 5,804 |
Selling, General & Admin | 1,241 | 2,091 | 2,371 | 2,584 | 3,082 | 3,048 |
Research & Development | 5,289 | 3,297 | 3,379 | 2,638 | 2,554 | 1,736 |
Other Operating Expenses | - | - | - | - | - | 4.34 |
Operating Expenses | 6,530 | 5,388 | 5,750 | 5,222 | 5,636 | 4,788 |
Operating Income | -5,613 | -4,441 | -3,877 | -812 | 1,964 | 1,016 |
Interest Expense | -108.88 | -149 | - | - | - | - |
Interest & Investment Income | 5.35 | 4 | 32 | 11 | - | 2.7 |
Currency Exchange Gain (Loss) | -36.63 | -64 | 172 | 117 | 136 | -20.19 |
Other Non Operating Income (Expenses) | -21.91 | 2 | -17 | -45 | -100 | 2.61 |
EBT Excluding Unusual Items | -5,775 | -4,648 | -3,690 | -729 | 2,000 | 1,001 |
Gain (Loss) on Sale of Assets | - | - | - | -7 | - | - |
Asset Writedown | -88.25 | -109 | -131 | -560 | - | - |
Other Unusual Items | 12.21 | 8 | 14 | 101 | 106 | 0.2 |
Pretax Income | -5,826 | -4,749 | -3,807 | -1,195 | 2,106 | 1,001 |
Income Tax Expense | 29.78 | 27 | 26 | 767 | 927 | -1,031 |
Net Income | -5,856 | -4,776 | -3,833 | -1,962 | 1,179 | 2,032 |
Net Income to Common | -5,856 | -4,776 | -3,833 | -1,962 | 1,179 | 2,032 |
Net Income Growth | - | - | - | - | -41.98% | - |
Shares Outstanding (Basic) | 55 | 50 | 45 | 40 | 39 | 38 |
Shares Outstanding (Diluted) | 55 | 50 | 45 | 40 | 40 | 39 |
Shares Change (YoY) | 19.47% | 11.34% | 13.02% | 0.75% | 1.97% | 17.88% |
EPS (Basic) | -106.24 | -95.12 | -84.99 | -49.17 | 30.19 | 53.04 |
EPS (Diluted) | -106.24 | -95.12 | -84.99 | -49.17 | 29.77 | 52.32 |
EPS Growth | - | - | - | - | -43.10% | - |
Free Cash Flow | - | -4,575 | -3,435 | -398 | 1,612 | 114.59 |
Free Cash Flow Per Share | - | -91.11 | -76.17 | -9.97 | 40.70 | 2.95 |
Gross Margin | 71.86% | 72.46% | 76.39% | 78.91% | 75.94% | 70.30% |
Operating Margin | -439.49% | -339.79% | -158.12% | -14.53% | 19.62% | 12.31% |
Profit Margin | -458.55% | -365.42% | -156.32% | -35.10% | 11.78% | 24.61% |
Free Cash Flow Margin | - | -350.04% | -140.09% | -7.12% | 16.11% | 1.39% |
EBITDA | - | - | -3,779 | -714 | 2,063 | 1,110 |
EBITDA Margin | - | - | -154.12% | -12.78% | 20.61% | 13.44% |
D&A For EBITDA | - | - | 98 | 98 | 99 | 93.96 |
EBIT | -5,613 | -4,441 | -3,877 | -812 | 1,964 | 1,016 |
EBIT Margin | - | - | -158.12% | -14.53% | 19.62% | 12.31% |
Effective Tax Rate | - | - | - | - | 44.02% | - |
Revenue as Reported | - | - | - | - | - | 8,257 |
Advertising Expenses | - | 540 | 692 | 937 | 1,481 | 1,643 |